The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 327.00
Bid: 328.50
Ask: 330.50
Change: -7.50 (-2.24%)
Spread: 2.00 (0.609%)
Open: 329.00
High: 332.50
Low: 321.00
Prev. Close: 334.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SMALL-CAP WINNERS & LOSERS: DFS Furniture gains share of weak market

Thu, 21st Sep 2023 09:40

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday.

----------

SMALL-CAP - WINNERS

----------

DFS Furniture PLC, up 4.9% 112.45p, 12-month range 101p-170p. The sofa retailer continues to win UK market share in a "very tough market" during its financial year, which ended on June 25, and outlines a path to improving margins. DFS says revenue from continuing operations fell 5.2% year-on-year to GBP1.09 billion from GBP1.15 billion, as pretax profit slumps 49% to GBP29.7 million from GBP58.5 million. Underlying profit before tax and brand amortisation is GBP30.6 million, which is in line with its interim guidance. DFS expects underlying profit before tax and brand amortisation to improve by a low single-digit percentage in financial 2024 to a GBP30 million to GBP35 million range. This assumes market volumes fall 5%, DFS notes. "We are confident the market will recover; however we can't predict how quickly that will happen. We have a clear route to a 5% [profit before tax] margin without market recovery, supported by further margin improvement, new cost efficiencies, and continued growth in Home," DFS says.

----------

Oxford BioMedica PLC, up 5.4% at 283.50 pence, 12-month range 236.50-575.00p. The cell and gene therapy company adds to Wednesday's gains after it announced exclusive talks with Institut Meriueux SA about buying ABL Europe, a pure-play European contract development and manufacturing organization. As part of the deal, Institut Merieux would become one of its major shareholders. The stock is down 16% over the past month however.

----------

SMALL-CAP - LOSERS

----------

James Fisher & Sons PLC, down 2.5% at 345.14p, 12-month range 241p-427.5p. The marine services swings to a pretax loss in the first half of 2023 of GBP4.4 million from a profit of GBP5.2 million a year before. This comes despite revenue rising 17% GBP252.0 million from GBP215.0 million. The loss is due to GBP9.3 million in refinancing legal and advisory costs, as well as higher interest rates, offsetting a positive operating performance, James Fisher explains. "All three divisions delivered revenue and profit growth against the first half of 2022, with a particularly strong increase seen in the Energy division," says CEO Jean Vernet. Trading in July and August is in line with its expectations, and James Fisher leaves its full-year expectations unchanged.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
10 Sep 2020 16:01

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
9 Sep 2020 08:31

Oxford Biomedica slumps as AstraZeneca vaccine trial halted

(Sharecast News) - Oxford Biomedica shares slid on Wednesday on news that AstraZeneca and Oxford University's Covid-19 vaccine trial has been put on hold, as investors fretted over how this might affect the gene and cell therapy company's supply deal with the UK pharmaceuticals giant.

Read more
1 Sep 2020 10:27

UPDATE 2-AstraZeneca bolsters COVID-19 vaccine supply with new deal

* AZ reserves production capacity at Oxford Biomedica plant* Deal could be expanded beyond new term of 18 months* AZ's drug, Imfinzi, also wins EU okay for aggressive lung cancer* AZ shares rise 1.5%, Oxford Biomedica up 2% (Adds comment on agreeme...

Read more
1 Sep 2020 10:27

CORRECTED-UPDATE 2-AstraZeneca bolsters COVID-19 vaccine supply with new deal

(Corrects para 3 to say EU (not U.S.) approval for Imfinzi)* AZ reserves production capacity at Oxford Biomedica plant* Deal could be expanded beyond new term of 18 months* AZ's drug, Imfinzi, also wins EU okay for aggressive lung cancer* AZ shares ...

Read more
1 Sep 2020 10:00

UPDATE 2-FTSE 100 falls to 15-week low after best August since 2014

(For a live blog on European stocks, type LIVE/ in an Eikon news window.)* FTSE 100 hit by strong pound, marks worst day since late July* Oxford Biomedica rises as AstraZeneca expands supply tie-up* British factory activity improves in August* Hom...

Read more
1 Sep 2020 08:29

UPDATE: Astra, Oxford Biomedica Expand Covid-19 Vaccine Supply Deal

UPDATE: Astra, Oxford Biomedica Expand Covid-19 Vaccine Supply Deal

Read more
1 Sep 2020 07:54

LONDON BRIEFING: Oxford Biomedica And Astra Expand Vaccine Supply Pact

LONDON BRIEFING: Oxford Biomedica And Astra Expand Vaccine Supply Pact

Read more
1 Sep 2020 07:54

CORRECTED-UPDATE 1-AstraZeneca, Oxford Biomedica expand COVID-19 vaccine supply tie-up

(Corrects currency in second paragraph to pounds from dollars)Sept 1 (Reuters) - AstraZeneca has expanded its previous agreement with Oxford Biomedica to mass-produce the British drugmaker's COVID-19 vaccine candidate, as it looks to scale-up supp...

Read more
1 Sep 2020 07:54

UPDATE 1-AstraZeneca, Oxford Biomedica expand COVID-19 vaccine supply tie-up

(Adds details on supply agreement, background)Sept 1 (Reuters) - AstraZeneca has expanded its previous agreement with Oxford Biomedica to mass-produce the British drugmaker's COVID-19 vaccine candidate, as it looks to scale-up supply ahead of a po...

Read more
1 Sep 2020 07:42

LONDON MARKET PRE-OPEN: Dunelm Sees Rise In Sales From Pent Up Demand

LONDON MARKET PRE-OPEN: Dunelm Sees Rise In Sales From Pent Up Demand

Read more
1 Sep 2020 07:35

CORRECTED-AstraZeneca expands COVID-19 vaccine supply tie-up with Oxford Biomedica

(Corrects currency in first paragraph to pounds from dollars)Sept 1 (Reuters) - AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID-19 vaccine candidate, in a deal that will pay the gene and cell t...

Read more
1 Sep 2020 07:35

AstraZeneca expands COVID-19 vaccine supply tie-up with Oxford Biomedica

Sept 1 (Reuters) - AstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID-19 vaccine candidate, in a deal that will pay the gene and cell therapy firm $15 million upfront and an additional $35 millio...

Read more
3 Aug 2020 08:05

Oxford Biomedica signs deal with Beam Therapeutics

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a new development, manufacture and license agreement with Beam Therapeutics, it announced on Monday, which it described as a Massachusetts-based biotechnology company developing precision genetic medicines through the use of base editing.

Read more
31 Jul 2020 11:06

IN BRIEF: Oxford Biomedica And Axovant Sign Clinical Supply Deal

IN BRIEF: Oxford Biomedica And Axovant Sign Clinical Supply Deal

Read more
31 Jul 2020 08:34

Oxford Biomedica signs supply deal with Axovant Gene Therapies

(Sharecast News) - Gene and cell therapy company Oxford Biomedica has signed a three-year clinical supply agreement with a wholly-owned subsidiary of Axovant Gene Therapies, it announced on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.